This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Create a Standout Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
Jazz (JAZZ) Up 16.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Discounted PEG Stocks for GARP Investors
by Urmimala Biswas
Although PEG is categorized under value investing, it follows the principles of both growth and value investing.
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up
by Zacks Equity Research
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
3 Reasons Growth Investors Will Love Jazz (JAZZ)
by Zacks Equity Research
Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle
by Zacks Equity Research
Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Catalyst Focuses on Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
Buy These 5 Top-Ranked Stocks With Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
by Zacks Equity Research
Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.
Jazz Pharmaceuticals plc (JAZZ) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Jazz Pharmaceuticals plc (JAZZ).
Tilray (TLRY) Looks Good: Stock Adds 7.2% in Session
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA
by Zacks Equity Research
The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.
Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
Bull of the Day: Jazz Pharma (JAZZ)
by David Bartosiak
The last earnings report has really jazzed things up
Why Jazz (JAZZ) Might be Well Poised for a Surge
by Zacks Equity Research
Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New Strong Buy Stocks for November 15th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Zacks.com featured highlights include: Lithia, KB, Anixter, Navient and Jazz
by Zacks Equity Research
Zacks.com featured highlights include: Lithia, KB, Anixter, Navient and Jazz
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Here is Why Growth Investors Should Buy Jazz (JAZZ) Now
by Zacks Equity Research
Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.